Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate

Rhea-AI Summary

Aktis Oncology (NASDAQ:AKTS) said the U.S. FDA granted Fast Track designation to AKY-1189 for adult patients with locally advanced or metastatic urothelial cancer who progressed after prior systemic therapies. AKY-1189 is an actinium-225 miniprotein radioconjugate targeting Nectin-4, which is expressed in approximately 80–90% of urothelial cancers.

Aktis is enrolling a multi-site Phase 1b trial (NCT07020117) across multiple Nectin-4 tumor types and expects to present preliminary Part 1 results in Q1 2027. Fast Track may enable more frequent FDA interactions and rolling BLA submission eligibility.

Positive

• FDA Fast Track designation for AKY-1189
• Nectin-4 expression in 80–90% of urothelial cancer
• Multi-site Phase 1b trial ongoing (NCT07020117)
• Preliminary Part 1 results expected in Q1 2027

Negative

• AKY-1189 remains in early-stage Phase 1b development
• No clinical efficacy or safety results publicly available yet

News Market Reaction – AKTS

+2.93%

2 alerts

+2.93% News Effect

+$29M Valuation Impact

$1.01B Market Cap

0.6x Rel. Volume

On the day this news was published, AKTS gained 2.93%, reflecting a moderate positive market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $29M to the company's valuation, bringing the market cap to $1.01B at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Nectin-4 expression rate: 80–90% Trial phase: Phase 1b Preliminary data timing: Q1 2027 +5 more

8 metrics

Nectin-4 expression rate 80–90% Urothelial cancer patients with positive Nectin-4 expression

Trial phase Phase 1b Ongoing AKY-1189 trial in multiple tumor types (NCT07020117)

Preliminary data timing Q1 2027 Expected preliminary results from Part 1 of AKY-1189 trial

IPO primary shares 17,650,000 shares Initial public offering at $18.00 per share

Underwriters’ option shares 2,647,500 shares Additional shares at $18.00 per share from IPO option

IPO gross proceeds $365.4 million Aggregate gross proceeds including overallotment

IPO raise (Vida note) $318 million Amount raised in IPO highlighted by Vida Ventures

Lilly collaboration value $1.2 billion Deal value of Eli Lilly strategic collaboration

Market Reality Check

Price: $20.54 Vol: Volume 297,406 is 21.4% a...

normal vol

$20.54 Last Close

Volume Volume 297,406 is 21.4% above the 20-day average of 245,098. normal

Technical Price at $19.43 is well above the 200-day MA of $3.12.

Peers on Argus

No peers in the provided sector list showed momentum, suggesting the move was st...

No peers in the provided sector list showed momentum, suggesting the move was stock-specific to AKTS rather than a sector rotation.

Historical Context

2 past events · Latest: Jan 13 (Positive)

Pattern 2 events

Date	Event	Sentiment	Move	Catalyst
Jan 13	IPO completion	Positive	-1.8%	Closed upsized IPO and underwriters’ option with substantial gross proceeds.
Jan 09	IPO highlight	Positive	+60115.1%	Backer highlights IPO raise, pipeline assets, and Eli Lilly collaboration value.

Pattern Detected

Limited history shows IPO-related news with one positive and one slightly negative next-day move, offering little established pattern yet.

Recent Company History

In early January 2026, Aktis completed an upsized IPO, issuing 17,650,000 shares at $18.00 plus an additional 2,647,500 shares through the underwriters’ option, for roughly $365.4 million in gross proceeds. A separate note from Vida Ventures highlighted a $318 million IPO raise, prior private funding of $346 million, and a collaboration with Eli Lilly valued up to $1.2 billion. Today’s FDA Fast Track designation for lead asset AKY-1189 builds on that financing and partnership backdrop as the company advances its clinical pipeline.

Market Pulse Summary

This announcement grants FDA Fast Track designation to AKY-1189 for advanced urothelial cancer, supp...

Analysis

This announcement grants FDA Fast Track designation to AKY-1189 for advanced urothelial cancer, supporting a Phase 1b program expected to yield preliminary data in Q1 2027. The news builds on Aktis’s recent IPO, which generated gross proceeds of $365.4 million, and a collaboration with Eli Lilly valued up to $1.2 billion. Investors may watch trial enrollment, emerging safety and efficacy data, and how AKY-1189 competes within the Nectin-4 targeted oncology landscape.

Key Terms

fast track designation, biologics license application, phase 1b, urothelial cancer, +4 more

8 terms

fast track designation regulatory

"U.S. FDA Fast Track designation granted to AKY-11891 for the treatment..."

A "fast track designation" is a process that speeds up the review and approval of a product or project, allowing it to reach the market or be completed more quickly than usual. For investors, it can signal that a product may become available sooner, potentially leading to earlier revenue or benefits, and indicating a priority status that might influence company performance and market opportunities.

biologics license application regulatory

"the ability to submit a Biologics License Application on a rolling basis."

A biologics license application is a formal request submitted to regulatory authorities seeking approval to market a new biological medicine, such as vaccines or treatments made from living organisms. It is a comprehensive review process that evaluates the safety, effectiveness, and manufacturing quality of the product. For investors, receiving approval signals that a biological therapy can be sold to the public, potentially leading to revenue growth and market success.

phase 1b medical

"Aktis is currently conducting a multi-site Phase 1b clinical trial..."

"Phase 1b" is an early stage in testing a new medical treatment or vaccine, where it is given to a small group of people to evaluate its safety and determine the right dose. For investors, this phase signals progress in development, indicating the treatment is advancing through initial safety checks, which can influence expectations for future success and potential market impact.

urothelial cancer medical

"for the treatment of adult patients with locally advanced or metastatic urothelial cancer..."

Urothelial cancer is a type of cancer that starts in the thin inner lining of the urinary tract — most commonly the bladder, but also the ureters, renal pelvis and urethra. It matters to investors because the size of the patient population, unmet medical needs, and success or failure of diagnostic tests and treatments drive clinical trial outcomes, regulatory approvals, pricing and market opportunity for companies developing therapies or diagnostics; think of it as a distinct market segment in oncology.

radioconjugate medical

"a Nectin-4 miniprotein radioconjugate platform, AKY-1189 is designed to deliver..."

A radioconjugate is a medicine made by attaching a small amount of radioactive material to a targeting molecule so the radiation is delivered directly to specific cells, like a guided missile carrying a tiny explosive to a precise address. Investors care because its safety, effectiveness, manufacturing complexity, and regulatory path determine development costs, market size and reimbursement potential, affecting a company’s future revenue and risk profile.

actinium-225 medical

"AKY-1189 is designed to deliver actinium-225 (225Ac), a highly potent..."

Actinium-225 is a rare, radioactive form of the metal actinium used as a microscopic radiation source in some cancer treatments; it emits very strong, short-range radiation that can destroy diseased cells when attached to a carrier drug. Investors pay attention because supply is limited and production is complex, so shortages or cost changes can directly affect the development, manufacturing and valuation of companies pursuing therapies that rely on this scarce medical “fuel.”

alpha-emitting radioisotope medical

"actinium-225 (225Ac), a highly potent alpha-emitting radioisotope, to Nectin-4..."

An alpha-emitting radioisotope is an unstable atom that releases heavy, high-energy particles (like tiny helium nuclei) as it decays; these particles travel only short distances but deliver intense localized damage. Investors care because these isotopes are used in targeted cancer treatments and some diagnostics, creating high-value markets but also demanding complex manufacturing, tight safety rules and regulatory approval—factors that can drive profits, costs and risk for companies involved.

clinical trial medical

"Aktis is currently conducting a multi-site Phase 1b clinical trial (NCT07020117)..."

A clinical trial is a carefully controlled study in which a new medicine, medical device, or treatment is tested on people to see if it is safe and effective. For investors it matters because trial results determine whether a product can win regulatory approval and reach patients, much like a road test decides if a new car can be sold; positive or negative results can sharply change a company’s prospects and stock value.

AI-generated analysis. Not financial advice.

• U.S. FDA Fast Track designation granted to AKY-1189¹ for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have progressed on or after prior systemic therapies
• Ongoing Phase 1b trial of AKY-1189 enrolling patients with locally advanced or metastatic urothelial cancer and several other Nectin-4 expressing tumor types

BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AKY-1189 for the treatment of adult patients with locally advanced or metastatic urothelial cancer (mUC) who have progressed on or after prior systemic therapies. Generated using Aktis’ miniprotein radioconjugate platform, AKY-1189 is designed to deliver actinium-225 (²²⁵Ac), a highly potent alpha-emitting radioisotope, to Nectin-4 expressing tumors. Approximately 80 – 90% of urothelial cancer patients show positive expression of Nectin-4.

Fast Track designation is an FDA process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. The purpose is to bring important new drugs to patients earlier. A drug that receives Fast Track designation may be eligible for more frequent interactions and communications with the FDA and the ability to submit a Biologics License Application on a rolling basis.

“Patients with locally advanced or metastatic urothelial cancer who progress on systemic therapies, such as PADCEV, have limited treatment options,” said Akos Czibere, MD, PhD, Chief Medical Officer of Aktis Oncology. “The granting of Fast Track designation affords us a unique opportunity to work closely with the FDA to potentially expedite the development and review process of AKY-1189 with the goal of addressing this unmet medical need by bringing a new therapeutic option to patients with locally advanced or metastatic urothelial cancer.”

Aktis is currently conducting a multi-site Phase 1b clinical trial (NCT07020117) of AKY-1189 in the United States for the treatment of locally advanced or mUC, breast cancer, non-small cell lung cancer, colorectal cancer, cervical cancer, and head and neck cancer. Aktis expects to present preliminary results from Part 1 of the trial in the first quarter of 2027.

About Aktis’ Radioconjugate Platform
Aktis has developed a proprietary, isotope-agnostic miniprotein radioconjugate platform to selectively deliver the tumor-killing properties of radioisotopes to targeted tumors. Aktis’ therapeutic miniprotein radioconjugates are designed to maximize anti-cancer activity through high penetration, internalization and retention in cancer cells, while quickly clearing from normal organs and tissues. The Aktis platform further enables clinicians to visualize and verify target engagement with imaging isotopes prior to exposure to therapeutic radioisotopes. Leveraging this platform, Aktis is advancing a pipeline of next-generation targeted radiopharmaceuticals to address the unmet needs of patients across a broad spectrum of solid tumors.

About Aktis Oncology
Aktis Oncology, Inc. is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. Aktis’ most advanced pipeline program, AKY-1189, is a miniprotein radioconjugate targeting Nectin-4, with multi-indication potential across multiple tumor types, including locally advanced or metastatic urothelial cancer, breast cancer, non-small cell lung cancer, colorectal cancer, cervical cancer, and head and neck cancer. Aktis’ second pipeline program, AKY-2519, is a miniprotein radioconjugate targeting B7-H3 expressing tumors, including prostate, lung and other solid tumors. Aktis has a strategic collaboration with Eli Lilly and Company to leverage its miniprotein platform to develop novel radioconjugates outside of Aktis’ proprietary pipeline.

Forward-Looking Statements
This communication contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, and other federal securities laws. Any statements contained herein which do not describe historical facts should be considered forward-looking statements, including, among others, the potential of AKY-1189 to treat locally advanced or metastatic urothelial cancer and other Nectin-4 expressing tumors, the anticipated timing of the Part 1 data from Aktis’ on-going Phase 1b clinical trial, the potential benefits conferred by Fast Track designation for AKY-1189; and Aktis’ plans with respect to the development of its product candidates, including AKY-1189.

Forward-looking statements are based on management's current beliefs and assumptions, which are subject to risks and uncertainties and are not guarantees of future performance. Such risks and uncertainties include, among others, the timing, scope, progress and results of Aktis’ research and development programs, preclinical studies, clinical trials, investigational new drug or biological license applications, and other regulatory submissions; the timing of, and costs involved in, obtaining and maintaining regulatory approval of AKY-1189 for locally advanced or metastatic urothelial cancer and other Nectin-4 expressing tumors, Aktis’ other product candidates, or any future product candidates that it may identify or develop; the ability to obtain an adequate supply at reasonable costs of ²²⁵Ac or any other radioisotope it may incorporate into its drug candidates; estimates regarding the market opportunities for Aktis’ drug candidates; Aktis’ intellectual property position, including the scope of protection it is able to establish, maintain, defend, protect and enforce for intellectual property rights covering its product candidates; the accuracy of Aktis’ estimates regarding future expenses, future revenue, capital requirements and need for additional financing; Aktis’ financial performance and its ability to effectively manage its anticipated growth; and such other risks and uncertainties identified in Aktis’ periodic, current and other filings with the Securities and Exchange Commission (SEC), including its final prospectus filed with the SEC on January 9, 2026 and any subsequent filings with the SEC, which are available at the SEC's website at www.sec.gov. Any such risks and uncertainties could materially and adversely affect Aktis’ results of operations and its cash flows, which would, in turn, have a significant and adverse impact on Aktis’ stock price. Aktis cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Aktis disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

Media Contact:
Melone Communications, LLC
Liz Melone
617-256-6622
liz@melonecomm.com

Investor Contact:
Precision AQ
Alex Lobo
212-698-8802
alex.lobo@precisionaq.com

^{____________________}

¹ AKY-1189 refers to the therapeutic radioconjugate [²²⁵Ac]Ac-AKY-1189.

FAQ

What did Aktis announce about AKY-1189 and FDA Fast Track on February 24, 2026 (AKTS)?

AKY-1189 received FDA Fast Track designation for progressed locally advanced or metastatic urothelial cancer. According to the company, Fast Track may enable more frequent FDA interactions and rolling BLA submission eligibility.

What is AKY-1189 and how does it target urothelial cancer (AKTS)?

AKY-1189 is a miniprotein radioconjugate delivering actinium-225 to Nectin-4 expressing tumors. According to the company, it targets Nectin-4, which is positive in about 80–90% of urothelial cancers.

What clinical trial is Aktis running for AKY-1189 and which cancers are included (AKTS)?

Aktis is conducting a multi-site Phase 1b trial (NCT07020117) enrolling mUC and other Nectin-4 tumors. According to the company, enrolled indications include breast, NSCLC, colorectal, cervical, and head and neck cancers.

When does Aktis expect to report preliminary AKY-1189 data and what phase is it (AKTS)?

Aktis expects to present preliminary Part 1 results in Q1 2027. According to the company, these results come from the ongoing Phase 1b trial across multiple sites in the United States.

How common is Nectin-4 expression in urothelial cancer relevant to AKY-1189 (AKTS)?

Approximately 80–90% of urothelial cancer patients show Nectin-4 expression. According to the company, that high prevalence supports targeting Nectin-4 with AKY-1189 in this patient population.

Does FDA Fast Track mean AKY-1189 is approved for urothelial cancer (AKTS)?

No, Fast Track does not equal approval; it expedites development and review processes. According to the company, Fast Track may allow more frequent FDA engagement and rolling BLA submission but does not guarantee approval.